Possibilities of clinical utilization of GnRH-test in menopause to identify the woman at risk for hormone-related pathology.
The authors evaluate the reliability of GnRH-Test in menopause in detecting the substratum at risk for the development of endometrial cancer. The study was carried out on 30 women affected with endometrial cancer and 30 controls; the examination of the individual curves of gonadotropin values in each patient led to observe LH preferential release in 23 out of 30 cancer patients and in 10 out of 30 controls. The difference of response between the two groups in highly statistically significant (0.0005 less than p less than 0.001). However, the predictive-value of the Test in relation to the detection of the substratum at risk, is about 70%; this apparently unsatisfactory result may be corrected by the finding that about 30% of endometrial cancers seem to develop independently from estrogens. GnRH-Test in menopause might then prove to be highly reliable in predicting the occurrence of estrogen-dependent endometrial malignancies, and may be particularly useful in detecting the substratum at risk among those women presenting no risk-factors, who otherwise might escape careful medical controls.
D004958:Estradiol / Q000096:biosynthesis; D004967:Estrogens; D005260:Female; D005640:Follicle Stimulating Hormone / Q000096:biosynthesis / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000096:biosynthesis / Q000378:metabolism; D008593:Menopause; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis*; D010906:Pituitary Hormone-Releasing Hormones; D011237:Predictive Value of Tests; D012306:Risk; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000378:metabolism
D004967:Estrogens; D010906:Pituitary Hormone-Releasing Hormones; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone